Microbot Medical Inc.
NASDAQ:MBOTMedical - Instruments & Supplies
-$0.06 today
- Market cap
- $65.73M
- Beta
- 1.04
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.21
Volume 0.87M
Average 1.60M
MBOT Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Microbot Medical Inc.NASDAQ: MBOT
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow outflow shrinks to $0
Q1 FY2026 financing cash flow was $0, compared with $27.81M a year earlier. Trailing-twelve-month financing cash flow was $58.43M. Over 3 fiscal years it compounded at +171.2% a year.
Context
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of $14.61M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 86.24M USD
- Year-over-year change
- +986.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 86.24M | +986.7% |
| FY2024 | 2024-12-31 | 7.94M | +21.0% |
| FY2023 | 2023-12-31 | 6.56M | +51.7% |
| FY2022 | 2022-12-31 | 4.32M | — |
| FY2021 | 2021-12-31 | 0 | — |
Financing Cash Flow vs competitors
How MBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +75.2% is the 7th highest of 10, against a peer median of +538.0%.
- Financing cash flow amounts to 55651.4% of revenue for MBOT, versus a peer median of 2758.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $2.46T USD | +7752625.5% | +101.8% | 816908.1% | |
| LTM Mar 2026 | $164.18M USD | +40238.1% | +646.7% | 2305.2% | |
| LTM Mar 2026 | $58.43M USD | +75.2% | +171.2% | 55651.4% | |
| LTM Mar 2026 | $33.16M USD | +538.4% | -28.4% | — | |
| LTM Mar 2026 | CA$29.19M CAD | +55.7% | — | — | |
| LTM Mar 2026 | $20.67M USD | +538.0% | +155.1% | 28.6% | |
| LTM Mar 2026 | $15.14M USD | -54.2% | — | — | |
| LTM Mar 2026 | $14.08M USD | +1110.6% | -12.6% | 10506.7% | |
| LTM Mar 2026 | CA$4.58M CAD | +152.1% | — | 2758.4% | |
| LTM Mar 2026 | $0 USD | -100.0% | -46.9% | — | |
| Peer median (excluding MBOT) | — | +538.0% | +44.6% | 2758.4% | |
Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (11.31M) | (13.17M) | (10.74M) | (11.44M) | (13.14M) |
| Depreciation & Amortization | 76K | 102K | 106K | 91K | 47K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.39M | 1.75M | 1.39M | 1.35M | 1.06M |
| Change in Working Capital | 497K | (228K) | (11K) | 942K | (1.01M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | (584K) |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 497K | (228K) | (11K) | 942K | (424K) |
| Other Non-Cash Items | 1.39M | (7K) | 718K | 234K | 0 |
| Operating Cash Flow | (9.35M) | (11.55M) | (8.53M) | (8.83M) | (13.05M) |
| Capital Expenditures | (69K) | (84K) | (33K) | (25K) | (60K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (3.75M) | (10.06M) | (5.12M) | (82.93M) |
| Sales of Investments | 3.27M | 0 | 12.06M | 6.68M | 10.6M |
| Other Investing Activities | 0 | (3K) | 3K | 0 | 0 |
| Investing Cash Flow | 3.2M | (3.84M) | 1.97M | 1.54M | (72.38M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 4.32M | 6.56M | 7.94M | 86.24M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 0 | 4.32M | 6.56M | 7.94M | 86.24M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.15M) | (11.06M) | (2K) | 646K | 810K |
| Free Cash Flow | (9.42M) | (11.63M) | (8.57M) | (8.85M) | (13.11M) |
Microbot Medical Inc.
NASDAQ:MBOT
Intrinsic Alpha fair value
Locked
Current Price
$0.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.